Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132498 | 0.85 | HPGD (0.37) | HPGDHCRTR1HCRTR2SMN1; SMN2KDM4E | |
| SCHEMBL4119657 | 0.85 | HPGD (0.34) | HPGDHCRTR1HCRTR2SMN1; SMN2KDM4E | |
| SCHEMBL13775495 | 0.84 | HPGD (0.34) | HPGDHCRTR1HCRTR2SMN1; SMN2KDM4E | |
| SCHEMBL4118491 | 0.78 | HCRTR1 (0.35) | HPGDHCRTR1HCRTR2KDM4EALDH1A1 | |
| SCHEMBL4118375 | 0.76 | HCRTR1 (0.37) | HPGDHCRTR1HCRTR2SMN1; SMN2KDM4E | |
| SCHEMBL4124239 | 0.75 | HCRTR1 (0.38) | HPGDHCRTR1HCRTR2SMN1; SMN2KDM4E | |
| SCHEMBL4118412 | 0.73 | HPGD (0.41) | HPGDHCRTR1HCRTR2SMN1; SMN2KDM4E | |
| SCHEMBL4111229 | 0.73 | MAPT (0.37) | ALDH1A1 | |
| SCHEMBL4122385 | 0.67 | HCRTR1 (0.38) | HPGDHCRTR1HCRTR2SMN1; SMN2KDM4E | |
| SCHEMBL4122687 | 0.66 | L3MBTL1 (0.44) | SMN1; SMN2KDM4EALDH1A1POLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | HPGD 1028/4885HCRTR1 1006/4885HCRTR2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.